Key PointsRed Spruce Capital increased its BSCT stake by 178,108 shares in the first quarter; the estimated trade value was $3.35 million based on quarterly average pricing.
Key PointsRed Spruce Capital increased its BSCT stake by 178,108 shares in the first quarter; the estimated trade value was $3.35 million based on quarterly average pricing.
CACI International ( CACI ) on Thursday said it has been awarded a seven-year technology contract valued at up to $287M by the U.S. Army’s Integrated Personnel and Pay System – Army (IPPS-A). "Under this contract, CACI will continue advancing towards a single, comprehensive solution to effectively operate and maintain IPPS-A Increment II, Managing Army’s Human Capital – Innovation, Integration, an...
CACI International ( CACI ) on Thursday said it has been awarded a seven-year technology contract valued at up to $287M by the U.S. Army’s Integrated Personnel and Pay System – Army (IPPS-A). "Under this contract, CACI will continue advancing towards a single, comprehensive solution to effectively operate and maintain IPPS-A Increment II, Managing Army’s Human Capital – Innovation, Integration, and Implementation (MAHC – III)," the company said. Source: Press Release More on CACI International CACI International Rightly Disputes Its Industry Classification: Oddly, That's Bullish CACI International Inc (CACI) Presents at Bank of America Global Industrials Conference 2026 Transcript CACI International Inc (CACI) Presents at 2026 Cantor Global Technology & Industrial Growth Conference Transcript CACI International prices $500M senior notes offering to fund ARKA acquisition CACI announces proposed offering of $500 million of senior notes due 2033
(RTTNews) - A report released by the Commerce Department on Thursday showed consumer prices in the U.S. increased in line with economist estimates in the month of February.
(RTTNews) - A report released by the Commerce Department on Thursday showed consumer prices in the U.S. increased in line with economist estimates in the month of February.
Stock index futures were lower before the opening bell as hopes of a resolution to the U.S.-Iran conflict waned following warnings from President Donald Trump of a major escalation. Here are the four stocks to watch on the day: CoreWeave ( CRWV ) rose 2.18% in premarket trading Thursday after the company announced an expanded long-term agreement with Meta Platforms to provide AI cloud capacity thr...
Stock index futures were lower before the opening bell as hopes of a resolution to the U.S.-Iran conflict waned following warnings from President Donald Trump of a major escalation. Here are the four stocks to watch on the day: CoreWeave ( CRWV ) rose 2.18% in premarket trading Thursday after the company announced an expanded long-term agreement with Meta Platforms to provide AI cloud capacity through December 2032, valued at ~$21 billion. The deal builds on an existing partnership and will support Meta’s AI development, with the company using CoreWeave’s platform to scale inference workloads. Chevron ( CVX ) gained 1.11% before the opening bell after the company said Thursday its first-quarter production fell as much as 6%, due in part to the Middle East war. In an 8-K filing, Chevron said it sees Q1 output averaging 3.8 million to 3.9 million barrels of oil equivalent per day, with volumes affected by downtime at Kazakhstan’s Tengizchevroil project as well as lower output from the Middle East, compared with 4.05 million boe/day during Q4 2025. Eli Lilly ( LLY ) edged up 0.02% in premarket trade after announcing Thursday that its newly approved weight loss pill Foundayo (orforglipron) will be available across U.S. retail pharmacies starting today. The launch sets up a battle with Novo Nordisk, which introduced its rival Wegovy pill earlier this year. When the FDA approved the once-daily therapy for obese or overweight adults with weight-related medical problems earlier this month, the company began immediately accepting Foundayo prescriptions through its direct-to-consumer site, LillyDirect. Tesla ( TSLA ) shares fell 0.2% before the opening bell as it said it was developing a smaller, lower-cost electric SUV, Reuters reported, citing four people familiar with the matter. The project is still in early stages, and it’s unclear whether Tesla has approved it for production. The company has recently approached suppliers to discuss details of the plan, according to the ...
If possible, Elon Musk’s recent appearance on the Moonshots with Peter Diamandis podcast may be the most sweeping claim he’s made yet. AI won’t just surpass human intelligence. It will do so by a margin so vast that humans become, in his words, a “microscopic minority” of intelligence not just on Earth but across the ... Elon Musk Says AI Will Exceed Human Intelligence to a Degree That Is Impossib...
If possible, Elon Musk’s recent appearance on the Moonshots with Peter Diamandis podcast may be the most sweeping claim he’s made yet. AI won’t just surpass human intelligence. It will do so by a margin so vast that humans become, in his words, a “microscopic minority” of intelligence not just on Earth but across the ... Elon Musk Says AI Will Exceed Human Intelligence to a Degree That Is Impossible to Fully Understand
Getty Images Morgan Stanley Overview Morgan Stanley’s ( MS ) setup going into Q1 still looks good to me. I’m sticking with a Buy call for anyone thinking medium or longer term. The company’s wealth management arm keeps showing it can hold up through all kinds of cycles; they’re really good at using capital efficiently, and there’s some extra upside that might come from new rules or policies that W...
Getty Images Morgan Stanley Overview Morgan Stanley’s ( MS ) setup going into Q1 still looks good to me. I’m sticking with a Buy call for anyone thinking medium or longer term. The company’s wealth management arm keeps showing it can hold up through all kinds of cycles; they’re really good at using capital efficiently, and there’s some extra upside that might come from new rules or policies that Wall Street hasn’t really priced in yet. MS stock is up about 35% since I last called it a buy . I’m not bumping it up to Strong Buy, mainly because the stock has already run so far and there are still some risks around, nothing super scary, but not just background noise either. Still, I think there’s more room for the shares to climb, both from how the market values the business and what they can send back to shareholders, as Morgan Stanley keeps growing and their core earnings seem less tied to wild swings in the economy than most people expect. Business Model Shift The Morgan Stanley of today isn’t the same as the one before 2020. They now have $9.3 trillion in client assets, and wealth management makes up over 40% of their total revenue. The big shift is that they don’t rely as much on trading gains; now they get a steady stream of fees. In the past year, they pulled in $70.6 billion in net revenue, up 14% from the year before. Net income for common shareholders hit $16.2 billion, up 27%. Earnings per share came in at $10.21, a 28% jump. Their expense efficiency ratio got better, moving to 68% from 71%, even while they kept investing in growth, so cost control is real, not just something management talks about. Return on tangible common equity reached 21.6%, and ROE was 16.6%. Both numbers are in line with or better than what management is aiming for in the next few years. Their CET1 capital ratio is 15.0%, Tier 1 leverage is 6.7%, and supplementary leverage stands at 5.4%, all well above what regulators require. Book value per share is now $64.37, and tangible book valu...